Got a book as a gift. Flipped to page two and found a story inspired by one of our @Sf500F startups: #unibaio . Such an unexpected moment of pride! Bravo @mfigliozzi
1
170
Fran Buchara retweeted
Demis Hassabis wants to cut drug discovery from 10 years to months.
Maybe one day weeks.
The CEO of Google DeepMind calls it science at digital speed:
1. Today a new drug takes about 10 years and billions of dollars
2. He sees biology as an information processing system
3. Maths became the language of physics. He thinks AI can be the language of biology
4. His spin-out, Isomorphic Labs, is rebuilding drug discovery on top of AlphaFold
5. The dream: a virtual cell where experiments run on a computer and the lab confirms them
AlphaFold took protein structures from years to seconds. Drugs are next on his list.
Full breakdown here:
theaiopportunities.com/p/dee…
Fran Buchara retweeted
this might be my last normal tweet before biotech goes vertical
i'm not a whistleblower. I don't work at Lilly, Novo or any of the big labs
but there is a massive shift happening in human biology right now.
it's sitting in press releases and almost nobody reads them
the last 6 months alone:
- a once-daily pill roughly doubled median survival in metastatic pancreatic cancer (13.2 vs 6.6 months)
- a one-time gene editing infusion cut hereditary angioedema attacks 87%, and 62% of patients stayed attack-free and off all other prevention for 6 months
- a one-time gene edit for cholesterol dropped LDL up to 62%, and it held for over a year
- a personalized mrna vaccine beat keytruda alone in a 1,137 patient melanoma phase 3
- retatrutide hit ~28% weight loss in a phase 3
- an ai-designed drug entered phase 3
- a pill that regrows hair passed its second phase 3
- an immunotherapy that could let some rectal cancer patients skip surgery, chemo and radiation just got fda approved
- a man lived 271 days off dialysis on a pig kidney
- human cells were caught passing chromosome-sized chunks of DNA to their neighbors, and it changes how the neighbors behave
we are on the verge of an era where the human body is a software problem and the update cycle gets shorter everyday
stick around, it's going to get weird
bio/acc
Fran Buchara retweeted
The best entrepreneur of the next decade is out there somewhere raising at a sub-$10m valuation and struggling to get it, building in a category investors aren't thinking about.
That's just how it works.
Fran Buchara retweeted
Advice is about to get very, very cheap
It should be obvious to everyone that information is now fully commoditized.
Advice is next, and it’s coming fast. The generic stuff — “Do I need an NDA before I show someone my idea?”
“C-corp or LLC?”
“How much equity does employee number three get?” — those kinds of answers are going to become instantly available to a founder in Lagos who doesn’t know a single other entrepreneur.
And I think that’s fantastic.
Fran Buchara retweeted
A person isn’t defined by one job title, one company, or one moment in time
Someone can be a founder, a parent, an investor, a student, and an artist, while continuing to learn and change, evolve
Our lives are more varied than the labels we use to describe them
Investing in a person means follows the human experience: they'll make it at some point, you're just not sure in which exact way
Fran Buchara retweeted
Over time, we’ve gotten good at placing bets on games, markets, and all kinds of uncertain outcomes
But some of the most meaningful upside lies in people, in what they’re learning, building, and becoming
What if we got better at backing them??
Fran Buchara retweeted
Las exportaciones argentinas de servicios basados en el conocimiento alcanzaron casi USD 10.500 millones.
Comparto este breve análisis realizado desde @Argencon
argencon.org/prensa-y-comuni…
Cuando una regulación habilita. Escribí porque creo que es importante el nuevo reglamento del @CONICETDialoga para startups nacidas de su ciencia. linkedin.com/pulse/cuando-un…
79
AI has collapsed the cost of building products, but not the cost of knowing what to build.
- The old loop: spec, scope, build
- The new loop: build, play, design, ship
Prototypes are cheap. Great products still require taste, judgment, and a clear understanding of what users actually need.
a16z's @joshelman on the artifact a product manager actually produces: a16z.news/p/product-manageme…
Fran Buchara retweeted
"there's 2 reasons why people go into science:
1. love uncovering new knowledge
2. want to impact the future state of the world
the first group just shouldn't start startups (truthnuke), because startups are not a great place to uncover new knowledge, science is actually better for that.
the latter group, the ones that want to change the future state of the world, a lot of them should become founders because someone's got to scale the science done in academia"
couldn't have said it better
building companies led by scientist-founders is @sethbannon's bread & butter. at @fiftyyears, he has backed 130+ companies, including 8 unicorns and 3 IPOs to date.
so what mistakes DO scientists-turned-founders repeat consistently? this, and many other questions, are answered in our latest episode of Under Pressure.
full episode on YT (link below)
Valeria Arredondo, CEO de @Beamcroptech, habló con @AireAgro sobre su tecnología para potenciar hasta 25% más la fotosíntesis en cultivos extensivos, y sobre los dos ensayos en campo clave para 2026: maíz en Missouri, en curso, y soja en Argentina.👇
aireagro.com.ar/agtech/una-t…
Marina Simian y Adriana de Siervi investigaron el cáncer durante años. En 2021 fundaron una empresa para llevar ese trabajo al mercado: un análisis de sangre que detecta los principales tipos de cáncer en etapas tempranas. El primer test, para cáncer de mama, sale este año.
🔗Leé más en la nota de @anto_journalist en nuestra web: forbesargentina.com/innovaci…
Tintte, startup del portfolio, en @impactedition: pigmentos a partir de microorganismos para reemplazar los tintes petroquímicos en la industria textil. Ya avanza con ensayos de fabricación en Argentina, Europa y Asia.
Mirá la completa 👇
impactedition.org/post/color…
👇 @Oncoliq: nota completa acá
forbesargentina.com/innovaci…
Se formaron en el CONICET y hoy dirigen las startups que ponen a la ciencia argentina en el mapa. Ocho investigadoras, más de US$ 40 millones levantados y una decisión en común: que un descubrimiento no se quede guardado en un paper.
Del cáncer (Oncoliq) a la fertilidad (Microgénesis), de los tumores (OncoPrecision) a los erizos de mar (Promarine), de los microbios de la Puna (Puna Bio) a la química verde (Bioeutectics) y las plantas que se defienden solas (Semion).
🔗 Leé más en la nota de @anto_journalist en nuestra web: forbesargentina.com






















